Product How it works Pricing Blog FAQ About Contact
Agios Pharmaceuticals

Agios Pharmaceuticals (NASDAQ: AGIO) revenue

Agios Pharmaceuticals reported revenue of $54.0m for fiscal 2025, 48.0% more than in fiscal 2024 ($36.5m). Since fiscal 2016 its revenue has fallen by 22.7%, an average decline of 2.8% a year.

Agios Pharmaceuticals has grown its revenue for 3 years in a row, and its best year of the last 10 was fiscal 2019. The biggest drop was in fiscal 2017, −38.5%.

Revenue, in millions of US dollars69.9201643.0201794.42018117.920190.020200.0202114.2202226.8202336.5202454.02025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$54.0m+48.0%−$472.1m−873.9%
2024$36.5m+36.1%−$425.7m−1,166.5%
2023$26.8m+88.4%−$391.5m−1,459.5%
2022$14.2m—−$389.0m−2,732.1%
2021$0.0m—−$378.4m—
2020$0.0m−100.0%−$335.9m—
2019$117.9m+24.9%−$316.3m−268.2%
2018$94.4m+119.4%−$362.5m−384.0%
2017$43.0m−38.5%−$320.8m−745.8%
2016$69.9m—−$201.0m−287.6%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Agios Pharmaceuticals revenue compared with its sector

By revenue for its latest fiscal year, Agios Pharmaceuticals ranks 324th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Agios Pharmaceuticals, 48.0%.

RankCompanyRevenueRevenue growth
322nd908 Devices$56.2m17.7%
323rdNektar Therapeutics$55.2m−43.9%
324thAgios Pharmaceuticals$54.0m48.0%
325thInvivyd$53.4m110.5%
326thProtalix Biotherapeutics$52.7m−1.2%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Agios Pharmaceuticals

How much revenue did Agios Pharmaceuticals make in fiscal 2025?
Agios Pharmaceuticals reported revenue of $54.0m for fiscal 2025, compared with $36.5m in fiscal 2024.
How much has the revenue of Agios Pharmaceuticals fallen?
Between fiscal 2016 and fiscal 2025 it went from $69.9m to $54.0m: 22.7% less, an average decline of 2.8% a year.
What was the best year for revenue at Agios Pharmaceuticals?
Of its last 10 fiscal years, fiscal 2019, with $117.9m.
Where does Agios Pharmaceuticals rank in its sector by revenue?
It ranks 324th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Agios Pharmaceuticals come from?
From the annual report (Form 10-K) that Agios Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Agios Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Agios Pharmaceuticals: the Agios Pharmaceuticals page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.